Registry Tracking Outcomes of Deep Brain Stimulation in Parkinson's Disease
Records outcomes of deep brain stimulation with a device in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Key facts
- Where
- Barcelona, Madrid, Murcia, Oviedo, and Valencia, SpainSee the 7 sites
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNo longer taking part
- Hospital De BellvitgeBarcelona, SpainNo longer taking part
- Centro Especial Ramon y CajalMadrid, SpainNo longer taking part
- Hospital Clínico San CarlosMadrid, SpainNo longer taking part
- University Hospital Virgen ArrixacaMurcia, SpainNo longer taking part
- Hospital General De AsturiasOviedo, SpainTaking people
- Hospital Universitario la FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boston Scientific Corporation
- Trial code
- NCT02071134
- Record updated
- 13 October 2026
- Original description
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.Read full original descriptionShow less
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Inclusion: Meets criteria established in locally applicable Vercise System Direction for Use; At least 18 years old.
Exclusion: Meets any contraindication in the Vercise System locally applicable Directions for Use; Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.